Loss of heterozygosity in tuberous sclerosis hamartomas

Tiina Sepp, John R W Yates, Andrew J Green

Abstract

We have previously described in tuberous sclerosis (TSC) hamartomas the phenomenon of loss of heterozygosity (LOH) for DNA markers in the region of both the TSC2 gene on chromosome 16p13.3 and the TSC1 gene on 9q34.

We now describe the spectrum of LOH in 51 TSC hamartomas from 34 cases of TSC. DNA was extracted from leucocytes or normal paraffin embedded tissue, and from frozen paraffin embedded hamartoma tissue from the same patient. The samples were analysed for 11 markers spanning the TSC1 locus and nine markers spanning the TSC2 locus. Twenty-one of 51 hamartomas showed LOH (41%). There was significantly more LOH on 16p13.3, with 16 hamartomas showing LOH around TSC2, and five in the vicinity of TSC1. No hamartoma showed LOH for markers around both loci. All the areas of LOH on chromosome 9 were large, but the smallest region of overlap lay between the markers D9S149 and D9S114, providing independent evidence for the localisation of the TSC1 gene.

These data show that LOH is a common finding in a wide range of hamartomas, affecting the same TSC locus in different lesions from the same patient but not affecting both loci. These data support the hypothesis that both the TSC genes act as tumour suppressors and that the manifestations of TSC in patients with germline TSC mutations rise from "second hit" somatic mutations inactivating the remaining normal copy of the TSC gene.

(*J Med Genet* 1996;33:962-964)

Key words: tuberous sclerosis; loss of heterozygosity; hamartoma.

Tuberous sclerosis (TSC) is an autosomal dominant condition characterised by tumour-like malformations (hamartomas) of the skin, brain, heart, kidney, and other organs. The disease prevalence is estimated at 1 in 10 000, with two thirds of cases being sporadic and representing new dominant mutations. Common hamartomas occurring in tuberous sclerosis include cortical tubers, subependymal nodules, retinal astrocytomas, renal an-

giomyolipomas, benign giant cell astrocytomas, and cardiac rhabdomyomas.

Two loci have been confirmed for TSC, with approximately 50% of familial cases linked to TSC1 at 9q34 and the remainder to TSC2 at 16p13.3.¹ The TSC1 gene lies in a 2.7 Mb region between markers D9S149 and D9S114.² The TSC2 gene has been cloned and about 5% of patients show large germline deletions of this gene.³ The predicted protein sequence has a short area of homology to a RAP1-GTPase activating protein (rap1GAP or GAP3), and the expressed TSC2 protein has rap1GAP activity in vitro.⁴

We and others have described the phenomenon of loss of heterozygosity (LOH) in the region of the TSC1 or TSC2 genes in hamartomas from cases of TSC.⁵⁻⁷ The presence of LOH on 16p13.3 in TSC hamartomas, and the finding of large germline deletions in the TSC2 gene in cases of TSC strongly suggest that the TSC2 gene acts as a tumour or growth suppressor, according to Knudson's hypothesis.⁸ The finding of LOH in TSC hamartomas for 9q34 suggests a similar role for the TSC1 gene. We now present our findings in a large series of TSC hamartomas.

We analysed 51 TSC hamartomas from 34 confirmed cases of TSC for LOH for markers on 9q34 and 16p13.3. The hamartomas consisted of 17 renal angiomyolipomas (AML), nine giant cell astrocytomas (GCA), eight fibromas, five cortical tubers, four cardiac rhabdomyomas, four renal cell carcinomas, one shagreen patch, one forehead plaque, one cutaneous keratoacanthoma, and one specimen of diffuse pulmonary lymphangioleiomyomatosis. Data on 13 of these samples have already been reported.^{5,6} Eleven of the 34 cases were familial, seven linked to the TSC1 gene, two to the TSC2 gene, and two from families too small to be allocated to one or other locus. The samples and normal DNA from the same case were analysed for 11 markers spanning the TSC1 locus and nine markers spanning the TSC2 locus. The markers on chromosome 9 were ASS, D9S64, D9S149, D9S1198, D9S150, ABO, DBH, D9S122, D9S298, D9S114, D9S67, and on chromosome 16 were D16S291, D16S665, KG8, a coding *EcoRV* polymorphism in exon 40 of the TSC2 gene, D16S525, D16S309, D16S85, and HBAP1.

Department of
Pathology, University
of Cambridge, UK

T Sepp
J R W Yates
A J Green

Department of
Medical Genetics,
Box 134,
Addenbrooke's NHS
Trust, Cambridge CB2
2QQ, UK

J R W Yates
A J Green

Department of
Medical Genetics,
University of
Cambridge, UK
A J Green

Correspondence to:
Dr Green.

Received 19 February 1996
Revised version accepted for
publication 17 June 1996

Figure 1 Map of loss of heterozygosity for markers on chromosome 9q34 in TSC hamartomas. The marker order is centromeric to telomeric from left to right. AML=renal angiomyolipoma, GCA=giant cell astrocytoma, RCC=renal cell carcinoma.

Twenty-one of 51 hamartomas showed LOH (41%) either in the region of the TSC1 locus or the TSC2 gene. No hamartoma showed LOH for markers around both loci. Five lesions showed LOH for markers around TSC1 (fig

1). The smallest area of LOH extended between the disease flanking markers D9S149 and D9S114, independently confirming the locus for TSC1 as defined by linkage analysis. Sixteen lesions showed variable LOH for markers in the region of the TSC2 gene (fig 2). A cortical tuber (TUB2) and cardiac rhabdomyoma (CRM) from the same case showed identical patterns of LOH and the same allele was lost in both hamartomas. The same phenomenon occurred in a shagreen patch and a cutaneous fibroma (FIB2 and SHP) from another case of TSC. We would interpret this finding cautiously, as the markers used represent discrete points along a genome, and the power of LOH studies is insufficient to map areas of somatic deletion effectively. There did not appear to be any major differences in the frequency of LOH between the different types of hamartoma. Seven of 17 renal angiomyolipomas showed LOH and five of nine giant cell astrocytomas showed LOH. Three of eight fibromas, three of five cortical tubers, a shagreen patch, a cardiac rhabdomyoma, and a renal cell carcinoma showed LOH. There was significantly more LOH for markers in the region of the TSC2 gene, with a χ^2 of 7.52 and a p value of <0.007. This excess of LOH for 16p13.3 confirms data from other workers studying TSC hamartomas and sporadic renal angiomyolipomas^{9,10} and may simply reflect that the TSC1 locus is less well defined, and therefore LOH for 9q34 is harder to find. These data show that LOH is a common finding, occurring in seven different types of hamartoma, including brain hamartomas. LOH occurs in the same TSC locus in different lesions from the same patient but does not affect both loci. These data support the hypothesis that both the TSC genes act as tumour suppressors, and that the manifestations of TSC in patients with germline TSC mutations arise from “second hit” somatic mutations inactivating the remaining normal copy of the TSC gene. Further LOH studies of TSC hamartomas will still be of benefit, as the finding

Figure 2 Map of loss of heterozygosity for markers on chromosome 16p13.3 in TSC hamartomas. The marker order is centromeric to telomeric from left to right. The two boxes connect hamartomas which both come from the same case of TSC. AML=renal angiomyolipoma, GCA=giant cell astrocytoma, RCC=renal cell carcinoma, TUB=tuber, CRM=cardiac rhabdomyoma, FIB=fibroma, SHP=shagreen patch.

of small areas of LOH on 9q34 may help refine the TSC1 interval.

We are grateful to the Tuberous Sclerosis Association (UK) for their support of tuberous sclerosis research in Cambridge. TS is funded by the Tuberous Sclerosis Association (UK). We thank Dr Philip Johnson for help with ABO typing. We are grateful to Dr David Kwiatkowski for providing the primer sequence data for the marker D9S1198. We thank all the clinicians and pathologists who allowed us access to patients and tissues.

- 1 Povey S, Burley MW, Attwood J, *et al.* Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. *Ann Hum Genet* 1994;58(pt 2):107-27.
- 2 Povey S, Armour J, Farndon P, *et al.* Report and abstracts of the Third International Workshop on Chromosome 9, Cambridge, United Kingdom, 9-11 April, 1994. *Ann Hum Genet* 1994;58(pt 3):177-250.
- 3 The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterisation of the tuberous sclerosis gene on chromosome 16. *Cell* 1993;75:1-11.
- 4 Wienecke R, Konig A, DeClue JE. Identification of tuberlin, the tuberous sclerosis-2 product. Tuberlin possesses specific Rap1GAP activity. *J Biol Chem* 1995;270:16409-14.
- 5 Green AJ, Smith M, Yates JRW. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. *Nat Genet* 1994;6:193-6.
- 6 Green AJ, Johnson PH, Yates JRW. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. *Hum Mol Genet* 1994;3:1833-4.
- 7 Carbonara C, Longa L, Grosso E, *et al.* 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. *Hum Mol Genet* 1994;3:1829-32.
- 8 Knudson AGJ. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci USA* 1971;68:820-3.
- 9 Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP, Kwiatkowski DJ. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. *Genes Chrom Cancer* 1995;13:295-8.
- 10 Carbonara C, Longa L, Grosso E, *et al.* Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. *Genes Chrom Cancer* 1996;15:18-25.